InVivoMAb anti-human CD40

Høglund RA, Bremel RD, Homan EJ, et al. CD4(+) T Cells in the Blood of MS Patients Respond to Predicted Epitopes From B cell Receptors Found in Spinal Fluid. Front Immunol. 2020,11:598. doi: 10.3389/fimmu.2020.00598

Cooley LF, Martin RK, Zellner HB, et al. Increased B Cell ADAM10 in Allergic Patients and Th2 Prone Mice. PLoS One. 2015,10(5):e0124331. doi: 10.1371/journal.pone.0124331

Bankert KC, Oxley KL, Smith SM, et al. Induction of an altered CD40 signaling complex by an antagonistic human monoclonal antibody to CD40. J Immunol. 2015,194(9):4319-27. doi: 10.4049/jimmunol.1402903

Okimura K, Maeta K, Kobayashi N, et al. Characterization of ASKP1240, a fully human antibody targeting human CD40 with potent immunosuppressive effects. Am J Transplant. 2014,14(6):1290-9. doi: 10.1111/ajt.12678

Frentsch M, Stark R, Matzmohr N, et al. CD40L expression permits CD8+ T cells to execute immunologic helper functions. Blood. 2013,122(3):405-12. doi: 10.1182/blood-2013-02-483586

Dumas G, Dufresne M, Asselin É, et al. CD40 pathway activation reveals dual function for macrophages in human endometrial cancer cell survival and invasion. Cancer Immunol Immunother. 2013,62(2):273-83. doi: 10.1007/s00262-012-1333-2

Price AM, Tourigny JP, Forte E, et al. Analysis of Epstein-Barr virus-regulated host gene expression changes through primary B-cell outgrowth reveals delayed kinetics of latent membrane protein 1-mediated NF-κB activation. J Virol. 2012,86(20):11096-106.

D'Souza BN, Edelstein LC, Pegman PM, et al. Nuclear factor kappa B-dependent activation of the antiapoptotic bfl-1 gene by the Epstein-Barr virus latent membrane protein 1 and activated CD40 receptor. J Virol. 2004,78(4):1800-16.

Francisco JA, Donaldson KL, Chace D, et al. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Cancer Res. 2000,60(12):3225-31.